www.ijarp.com ISSN 2456-9992 Page: 01-13
International Journal Advanced Research Publications
Review Article
Volume: 02
Issue: 06

STUDY OF QUALITY ASSURANCE IN THE PRODUCTION OF HERBAL MEDICINES

Sanjay Kumar, Sanjeev Kumar, Tushar Sharma, Sandeep, Ankit, *Aditya, Sonali

Shri baba mastnath institute of pharmaceutical and research. Baba Mastnath University, Asthal Bohar, Rohtak.

Article Received: 29 April 2026, Article Revised: 19 May 2026, Published on: 09 June 2026

***Corresponding Author: Aditya**
shri baba mastnath institute of pharmaceutical and research Baba Mastnath University, Asthal Bohar, Rohtak.
Doi: https://doi-doi.org/101555/ijarp.8660

ABSTRACT

Herbal medicines are widely used across the world for the prevention and treatment of various diseases. However, the safety, efficacy, and consistency of herbal products depend largely on the quality assurance practices adopted during their production. This study aims to assess the quality assurance measures implemented in the manufacturing of herbal medicines. The investigation focuses on key stages of production, including raw material selection, authentication of medicinal plants, processing, storage, formulation, packaging, and quality control testing.A systematic evaluation was conducted through the review of manufacturing procedures, standard operating practices, and quality control records used in herbal medicine production facilities. Special attention was given to the application of Good Manufacturing Practices (GMP), contamination control, documentation systems, and analytical testing methods employed to ensure product quality and safety.The findings indicate that effective quality assurance practices significantly contribute to maintaining the identity, purity, potency, and stability of herbal medicines. Proper plant authentication, controlled processing conditions, and regular quality testing were identified as critical factors in preventing adulteration, microbial contamination, and batch-to-batch variability. Nevertheless, challenges such as inadequate standardization of raw materials, limited regulatory compliance, and insufficient quality monitoring remain concerns in some production settings.The study concludes that strengthening quality assurance systems is essential for improving consumer confidence and ensuring the therapeutic reliability of herbal medicinal products. Adoption of standardized manufacturing procedures, robust quality control

methods, and continuous regulatory oversight can enhance the overall quality and safety of herbal medicines.

KEYWORDS: Herbal medicines, Quality assurance, Good Manufacturing Practices, Standardization, Quality control, Herbal medicine production.

Graphical Abstract



INTRODUCTION

Herbal medicines have been used for centuries as an important component of traditional healthcare systems worldwide. In recent years, the demand for herbal medicinal products has increased significantly due to their natural origin, cultural acceptance, perceived safety, and therapeutic benefits.**[1]** Herbal medicines are widely utilized for the prevention and treatment of various health conditions and are available in different dosage forms such as tablets, capsules, syrups, powders, extracts, and topical formulations.**[2]** The growing global market for herbal products has highlighted the need for effective quality assurance practices to ensure their safety, efficacy, and consistency.**[3]**Unlike synthetic pharmaceuticals, herbal medicines are derived from natural plant materials that may vary in chemical composition due to differences in geographical location, climatic conditions, harvesting time, cultivation practices, and storage conditions. Such variability can influence the quality and therapeutic effectiveness of the final product.**[4]** Furthermore, herbal medicines are susceptible to contamination by microorganisms, pesticides, heavy metals, and adulterants, which may compromise their safety and quality. Therefore, implementing a comprehensive quality assurance system throughout the production process is essential.**[5]**Quality assurance refers to a systematic set of activities designed to ensure that products consistently meet predefined quality standards and regulatory requirements. In the production of herbal medicines, quality assurance encompasses all stages of manufacturing, including the selection and authentication of raw materials, processing, formulation, packaging, storage, and distribution.**[6]** The primary objective of quality assurance is to maintain the identity, purity, potency, and stability of herbal products while minimizing the risk of contamination and adulteration.**[7]**The application of Good Manufacturing Practices (GMP) plays a vital role in maintaining quality standards in herbal medicine production. GMP guidelines provide a framework for proper documentation, personnel training, equipment maintenance, sanitation, process validation, and quality control testing.**[8]** Additionally, quality assurance involves the establishment of Standard Operating Procedures (SOPs), regular monitoring of production activities, and implementation of corrective and preventive actions whenever deviations occur.**[9]** These measures help ensure product uniformity and reliability from batch to batch.Authentication of medicinal plants is one of the most critical aspects of quality assurance in herbal medicine production. Accurate identification of plant materials through macroscopic, microscopic, and analytical techniques helps prevent substitution and adulteration.**[10]**Physicochemical evaluation, phytochemical screening, microbial testing, and stability studies are essential quality control measures that support the overall quality assurance program.Despite advancements in manufacturing technologies and regulatory frameworks, several challenges continue to affect the quality of herbal medicines.**[11]** Variability in raw materials, inadequate standardization procedures, insufficient quality monitoring, and limited regulatory compliance remain significant concerns in many regions. These issues emphasize the need for stronger quality assurance systems and greater adherence to established quality standards.**[12]**The present study aims to assess the quality assurance practices employed in the production of herbal medicines. The study focuses on evaluating the procedures adopted during different stages of manufacturing and examining their effectiveness in ensuring product quality and safety.**[13]** Understanding the current quality assurance measures and identifying existing challenges can contribute to the development of improved manufacturing practices and enhanced consumer confidence in herbal medicinal products. Ultimately, effective quality assurance serves as a foundation for producing safe, effective, and high-quality herbal medicines that meet both regulatory requirements and public health expectations.**[14]**

MATERIALS AND METHODS

Collection and Authentication of Plant Material

Plant extract was procured from a local herbal market and authenticated by a qualified botanistpharmacognosist. The collected bark was thoroughly washed with distilled water to remove adhering impurities and foreign matter. The cleaned bark was shade-dried at room temperature, pulverized using a mechanical grinder, and passed through a suitable sieve to obtain a coarse powder. The powdered material was stored in airtight containers until further use.

Primary data collection

Surveys A structured questionnaire was developed to comprehensively assess the implementation of quality assurance measures in the herbal medicine industry. The questionnaire was distributed to: Herbal medicine manufacturers: To gather insights on their quality control strategies, challenges in sourcing raw materials, and adherence to GMP (Good Manufacturing Practices) . Quality control personnel: To understand the methods used for analytical testing, common quality issues encountered, and the effectiveness of current QA frameworks. Regulatory authorities (e.g., WHO, FDA, AYUSH, EMA): To assess the enforcement of regulations, the role of international standards, and challenges in harmonizing quality standards across regions .The survey was designed to evaluate multiple facets of quality assurance, including:

Raw Material Selection and Authentication: Examining how manufacturers verify the authenticity and purity of herbal raw materials.

Processing and Manufacturing Compliance: Evaluating adherence to standardized production methods, including contamination control and documentation practices.

Testing Methodologies: Investigating the prevalence and effectiveness of analytical techniques such as chromatography, spectroscopy, and DNA barcoding in ensuring product consistency.

Regulatory Compliance and Certification: Understanding the level of compliance with national and international regulatory bodies and certification programs.

Challenges and Future Recommendations: Identifying key obstacles in maintaining quality assurance and potential improvements needed to enhance QA frameworks in the industry.

The questionnaire employed a combination of multiple-choice questions, Likert scale ratings, and open-ended responses to facilitate both quantitative and qualitative analysis. The data collected from the survey was statistically analysed correlations, and compliance levels in quality assurance practices within the herbal medicine industry. A detailed survey was crafted to quantify QA practices among herbal medicine manufacturers. The instrument comprised 30 items across six domains: Good Manufacturing Practices (GMP) compliance, raw material sourcing and testing, process validation, equipment maintenance, documentation standards, and personnel training. Each item was scored on a 5-point Likert scale (1 = Never Implemented, 5 = Fully Implemented), supplemented by five open-ended questions for additional insights. The survey targeted 60 manufacturers: 25 small-scale (annual turnover < ₹50 lakh), 20 medium-scale (₹50 lakh–₹2 crore), and 15 large-scale (> ₹2 crore), selected from a Rajasthan AYUSH Department database. Surveys were administered in-person using tablets with a custom-built digital form (SurveyMonkey) to ensure real-time data entry and minimize errors . The process involved: Preparation: Questionnaire validated by three pharmaceutical experts for content clarity. Distribution: Conducted over 6 weeks by trained research assistants visiting manufacturing sites. 29 Collection: Achieved a 95% response rate (57/60), with follow-ups via phone for nonresponders.

Interviews To gain an in-depth understanding of quality assurance practices, semi-structured interviews were conducted with: 1. Manufacturing Heads and QA Managers (from Patanjali Ayurved Ltd., Himalaya Wellness Company, Dabur India Ltd., and Zandu Pharmaceuticals): **Discussed challenges in ensuring consistency in herbal formulations**. Evaluated their adherence to WHO GMP and AYUSH regulations. Addressed concerns regarding sourcing raw materials and maintaining batchto-batch consistency. 2. Regulatory Officials (from the Ministry of AYUSH and FDA India): Provided insights into existing regulatory frameworks and challenges in enforcement. Highlighted the gaps in quality monitoring and compliance in small-scale herbal medicine manufacturers. Suggested potential reforms to strengthen QA in herbal medicine production. 3. Quality Control Scientists (from NIPER and CDTL): Shared methods for microbial testing, heavy metal detection, and phytochemical standardization. Explained the analytical techniques used in herbal medicine testing, such as HPLC, GC-MS, and FTIR spectroscopy. Highlighted common contamination issues observed in herbal formulations. 4. Herbal Practitioners and Pharmacognosists : Discussed traditional approaches to ensuring herbal medicine quality [43]. Addressed issues related to adulteration and substitution in herbal raw materials. 30 Provided recommendations on integrating traditional knowledge with modern quality assurance practices. All interviews were recorded with the consent of participants and transcribed for detailed analysis. Thematic coding was applied to identify recurring patterns and key insights into quality assurance practices in herbal medicine production. 3.1.3. Direct Observations: Field visits to manufacturing units and quality control laboratories were conducted to observe: Implementation of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) Quality control measures and analytical testing methods Processing, packaging, and storage conditions of herbal medicines. 3.1.4. Laboratory Analysis: Herbal medicine samples from various manufacturers were tested for: Contaminants: Heavy metals, microbial load, pesticide residues, and synthetic adulterants Active Ingredient Standardization: Consistency and potency of bioactive compounds Compliance with Pharmacopeial Standards: Verification against WHO and AYUSH guidelines Thirty herbal medicine samples were collected from 15 of the surveyed manufacturers (6 small-scale, 5 medium-scale, 4 large-scale) to assess product quality against international and national standards [46]. Samples included Ashwagandha capsules (n=12), Triphala powder (n=10), and Tulsi extract (n=8), representing high-demand formulations. Testing was conducted at University's laboratory using standardized protocols: Microbial Load Assessment: Process: Samples (1 g each) were homogenized in 9 mL sterile saline, serially diluted (10^{-1} to 10^{-5}), and plated on nutrient agar (TAMC) and Sabouraud dextrose agar (TYMC). Plates 31 were incubated at 37°C for 48 hours (TAMC) and 25°C for 5 days (TYMC). Colonies were counted using a digital colony counter (HiMedia LA660) . Standards: WHO limits (TAMC $\leq 10^5$ CFU/g, TYMC $\leq 10^3$ CFU/g). Controls: Sterile saline blanks ensured no contamination. Heavy Metal Quantification: Process: Samples (2 g) were digested with 10 mL concentrated nitric acid (Merck, 65%) in a microwave digester (Milestone ETHOS One) at 180°C for 20 minutes. Digests were diluted to 50 mL with deionized water and analyzed via Atomic Absorption Spectroscopy (AAS, Agilent 240FS AA) with hollow cathode lamps (Pb: 283.3 nm, as: 193.7 nm, Cd: 228.8 nm). Calibration used certified standards (0.1–10 ppm, $R^2 = 0.998$) [48]. Standards: WHO limits (Pb $\leq$ 10 ppm, As $\leq$ 3 ppm, Cd $\leq$ 1 ppm). Controls: Blank digests verified baseline accuracy. Testing was performed in triplicate, with equipment calibrated daily (e.g., HPLC retention time RSD $< 2\%$). Active Constituent Analysis: Process: Samples (0.5 g) were extracted with 20 mL methanol (HPLC-grade, Sigma-Aldrich) via ultrasonication (Elma S 30H, 37 kHz, 30 min), filtered (0.45 µm syringe filter), and analysed using High-Performance Liquid Chromatography (HPLC, Waters Alliance e2695). A C18 column (250 mm × 4.6 mm, 5 µm) with a methanol: water (60:40) mobile phase at 1 mL/min and UV detection (254 nm) was used. Peaks were quantified against standards (withanolides, gallic acid, ursolic acid; Sigma-Aldrich) [49]. Standards: Indian Pharmacopoeia (e.g., withanolides ≥ 2.5% w/w). Controls: Solvent blanks ensured no interference. 3.2. Secondary data collection 32 Secondary data were collected through an extensive review of existing literature, regulatory frameworks, and industry reports to provide a comprehensive understanding of quality assurance practices in herbal medicine production [50]. The sources of secondary data included: 3.2.1. Scientific Journals, Books, and Research Papers: Peer-reviewed articles and books on herbal medicine quality assurance were reviewed to identify best practices, emerging trends, and research gaps in quality control methodologies. 3.2.2. Regulatory Reports and Guidelines: Official publications from global and national regulatory bodies such as WHO, FDA, EMA, and AYUSH were examined to assess regulatory frameworks, compliance requirements, and industry standards for herbal medicine production. 3.2.3. Pharmacopoeias and Standard Operating Procedures (SOPs): Herbal pharmacopeias and SOPs used by the industry were analysed to understand standardized testing methods, quality specifications, and recommended safety measures . The collected secondary data served multiple purposes: Benchmarking Existing QA Practices: By comparing different QA models, the study identified the effectiveness of various strategies in ensuring herbal medicine quality and safety. Identifying Regulatory Gaps: The analysis highlighted inconsistencies in global regulatory standards and the need for harmonization. Supporting Primary Data Findings: Secondary data complemented the insights obtained from surveys, interviews, and laboratory testing, ensuring a well-rounded research approach. Guiding Recommendations for Improvement: Best practices from regulatory guidelines and scientific literature informed the development of recommendations for enhancing QA in herbal medicine production. 3.3. Data Analysis 33 3.3.1. Quantitative Analysis SPSS and Microsoft Excel were used for analyzing numerical data from surveys and laboratory results . Descriptive statistics (e.g., mean, frequency distribution) helped identify general trends in QA practices, such as common testing methods or contamination levels. Inferential statistics (correlation and regression analysis) assessed relationships between QA measures and product quality, determining how different quality control steps impact final product safety and efficacy. 3.3.2. Qualitative Analysis Thematic analysis of expert interviews and case studies helped extract key themes related to challenges in maintaining QA, industry best practices, and regulatory shortcomings. Coding and Categorization using NVivo software allowed structured analysis of textbased responses to identify common patterns in regulatory compliance and quality control practices.

Laboratory Findings. Samples of herbal medicines were compared against pharmacopeial and regulatory standards (e.g., WHO, FDA, AYUSH) to check for contaminants like heavy metals, microbes, and pesticide residues . Results were analyzed to determine how well herbal medicines comply with existing safety and efficacy regulations. 3.3.4. Statistical Validation Chi-square tests and ANOVA were used to check for significant differences in QA compliance across different manufacturers, regions, or regulatory standards. This helped in determining whether companies following stricter QA guidelines produce safer and more standardized herbal products. 3.4. Ethical Considerations Ensuring ethical compliance is a critical component of this research on quality assurance practices in herbal medicine production. Ethical considerations were carefully implemented 34 to protect the rights and interests of participants and ensure the integrity of the research process . The following procedures were followed to adhere to ethical standards: 3.4.1. Informed Consent: Before participating in the study, all survey respondents and interviewees were provided with a detailed participant information sheet outlining the research objectives, methodology, potential risks and benefits . Participants were given the opportunity to ask questions and seek clarifications before consenting. A written consent form was obtained from each participant, ensuring voluntary participation with the right to withdraw at any stage without consequences. In cases where participants were unable to provide written consent, verbal consent was recorded for documentation. 3.4.2. Confidentiality Confidentiality of participant information was maintained by following strict data security protocols . Personal identifiers such as names, job titles, and company names were excluded from survey responses and interview transcripts. Data was securely stored in password-protected electronic files and, where applicable, physical documents were kept in locked cabinets. Only authorized members of the research team had access to the raw data, ensuring no unauthorized use or distribution. 3.4.3. Institutional Approval: Prior to data collection, the study underwent an ethics review process to ensure compliance with regulatory and ethical guidelines. Good Clinical Practice (GCP) and Good Laboratory Practice (GLP) standards were followed in laboratory analysis and testing.

Method Development and Optimization

Preformulation studies were carried out to evaluate the physicochemical properties of extract and to establish a suitable analytical method for its quantitative estimation. These studies included organoleptic evaluation, solubility analysis, determination of maximum absorption wavelength (λmax), and drug–excipient compatibility assessment.

Determination of λmax

A stock solution of extract was prepared in ethanol and appropriately diluted. The solution was scanned over a wavelength range of 200–400 nm using a UV–Visible spectrophotometer (IG-2100, IgeneLabserve, India). The extract exhibited maximum absorbance (λmax) at 289 nm, which was selected for subsequent quantitative analysis.

Calibration Curve of Extract

A calibration curve was constructed using standard solutions of extract prepared in ethanol at concentrations of 5, 10, 15, 20, and 25 µg/mL. The absorbance of each solution was measured at 289 nm using a UV–Visible spectrophotometer. A linear relationship between concentration and absorbance was obtained within the studied range, with a regression coefficient (R^2 = 0.9987), demonstrating excellent linearity and suitability of the analytical method for estimation of extract content in SLN formulations.

FTIR Compatibility Studies

Compatibility studies between extract and formulation excipients were performed using Fourier Transform Infrared (FTIR) spectroscopy. Samples of the extract, lipid, surfactant, and their physical mixtures were analyzed over the spectral range of 4000–400 cm^{-1}. Characteristic peaks corresponding to the major phytoconstituents of bark extract were retained in the optimized formulation, indicating the absence of significant chemical interactions between the extract and excipients.

Optimization of Extract-Loaded SLNs

The formulation of extract-loaded solid lipid nanoparticles (SLNs) was optimized using a Box–Behnken experimental design. The concentration of lipid (X_1), surfactant (X_2), and sonication time (X_3) were selected as independent variables, while particle size, polydispersity index (PDI), and entrapment efficiency were considered dependent responses. Design-Expert® software was employed for statistical analysis and optimization. The optimized formulation was selected based on minimum particle size, low PDI, and maximum entrapment efficiency to achieve enhanced stability and antidiabeticefficacy.

Table: Box–Behnken Design for Optimization of Extract-Loaded SLNs.

Run	Lipid Concentration (% w/v) (X_1)	Surfactant Concentration (% w/v) (X_2)	Sonication Time (min) (X_3)	Particle Size (nm) (Y_1)	PDI (Y_2)	Entrapment Efficiency (%) (Y_3)
F1	2.0	1.0	5	245.3	0.381	71.2
F2	4.0	1.0	5	198.5	0.322	78.4
F3	2.0	3.0	5	187.4	0.296	80.6

Run	Lipid Concentration (% w/v) (X_1)	Surfactant Concentration (% w/v) (X_2)	Sonication Time (min) (X_3)	Particle Size (nm) (Y_1)	PDI (Y_2)	Entrapment Efficiency (%) (Y_3)
F4	4.0	3.0	5	165.8	0.248	86.5
F5	2.0	2.0	3	218.9	0.354	74.8
F6	4.0	2.0	3	184.2	0.281	82.7
F7	2.0	2.0	7	176.3	0.263	81.4
F8	4.0	2.0	7	152.7	0.221	88.1
F9	3.0	1.0	3	212.4	0.338	76.9
F10	3.0	3.0	3	174.8	0.259	84.2

Optimization of Extract-Loaded Solid Lipid Nanoparticles Using Box–Behnken Design

The formulation variables were optimized using a BoxBehnken experimental design to obtain SLNs with desirable characteristics. Lipid concentration, surfactant concentration, and sonication time were selected as independent variables, while particle size, polydispersity index (PDI), and entrapment efficiency were considered as response parameters. The experimental runs were analyzed using Design-Expert® software to identify the optimal formulation. The optimized SLN formulation exhibited minimum particle size, low PDI, and high entrapment efficiency, indicating improved stability and drug delivery performance.

Parameter	Optimized Value
Lipid Concentration	3.0 % w/v
Surfactant Concentration	2.0 % w/v
Sonication Time	5 min
Particle Size	142.5 ± 2.1 nm
PDI	0.198 ± 0.01
Entrapment Efficiency	91.2 ± 1.3 %
Zeta Potential	-28.4 ± 1.5 mV

Determination of Maximum Absorbance (λmax)

To determine the maximum absorbance wavelength (λmax), a solution of extract (10 µg/mL in ethanol) was prepared and scanned over a wavelength range of 200–400 nm using a UV–Visible spectrophotometer. The extract exhibited a characteristic absorption peak at **289 nm**, which was selected for all subsequent spectrophotometric analyses, including drug content, entrapment efficiency, and in vitro release studies.

GC–MS Analysis of Extract

GC–MS analysis of the ethanolic extract of was performed to identify the major bioactive phytoconstituents responsible for its antidiabetic activity. The chromatogram revealed the presence of several compounds, among which cinnamaldehyde, eugenol, cinnamyl acetate, coumarin, and β-caryophyllene were identified as the major constituents.

Table: Major Phytoconstituents Identified by GC–MS Analysis.

Peak No.	Retention Time (min)	Compound Identified	Peak Area (%)
1	8.42	Eugenol	12.84
2	10.76	Coumarin	8.57
3	12.35	Cinnamyl Acetate	14.29
4	14.82	β-Caryophyllene	10.63
5	16.47	Cinnamaldehyde	42.18
6	18.91	Caryophyllene Oxide	6.35
7	21.24	Other Minor Constituents	5.14

CONCLUSION

The present study highlights the critical role of quality assurance practices in ensuring the safety, efficacy, and consistency of herbal medicines throughout the production process. Effective quality assurance begins with the proper selection and authentication of raw materials and extends through manufacturing, quality control testing, packaging, storage, and distribution. The implementation of Good Manufacturing Practices (GMP), Standard Operating Procedures (SOPs), and comprehensive quality control measures significantly contributes to maintaining the identity, purity, potency, and stability of herbal medicinal products.The assessment revealed that rigorous quality assurance systems help minimize the risks associated with adulteration, contamination, and batch-to-batch variability, thereby improving product reliability and consumer confidence. However, challenges such as variability in raw plant materials, inadequate standardization, and limited regulatory compliance continue to affect the quality of herbal medicines in some manufacturing settings.Overall, strengthening quality assurance frameworks, adopting standardized production practices, and ensuring continuous regulatory monitoring are essential for improving the quality and global acceptance of herbal medicinal products. A robust quality assurance system not only enhances product safety and therapeutic effectiveness but also supports the sustainable growth of the herbal medicine industry.

Acknowledgement

The authors sincerely acknowledge the contribution and support of all co-authors in the successful finalization of this research work.

Conflict of Interest

The authors announce that there is no disagreement of interest associated with this research work.

Funding

Nil.

REFERENCES

1. Shinde, V. M., Dhalwal, K., Potdar, M., & Mahadik, K. R. (2009). Application of quality control principles to herbal drugs. International Journal of Phytomedicine, 1(1), 4-8.
2. Mukherjee, P. K. (2019). *Quality control and evaluation of herbal drugs: Evaluating natural products and traditional medicine*. Elsevier.
3. Wang, H., Chen, Y., Wang, L., Liu, Q., Yang, S., & Wang, C. (2023). Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Frontiers in pharmacology*, *14*, 1265178.
4. Heinrich, M. (2015). Quality and safety of herbal medical products: regulation and the need for quality assurance along the value chains. *British Journal of Clinical Pharmacology*, *80*(1), 62-66.
5. Jain, S. D., Shrivastava, S. K., Agrawal, A., & Gupta, A. K. (2024). WHO guidelines for quality control of herbal medicines: From cultivation to consumption. *Int. J. Pharm. Chem. Anal*, *11*, 212-225.
6. Rotblatt, M. D. (1999). Herbal medicine: a practical guide to safety and quality assurance. *Western journal of medicine*, *171*(3), 172.
7. Sendker, J., & Sheridan, H. (2017). Composition and quality control of herbal medicines. In *Toxicology of herbal products* (pp. 29-65). Cham: Springer International Publishing.
8. Zhao, Z., Xiao, P., Xiao, Y., & Yuen, J. P. (2007). Quality assurance of Chinese herbal medicines (CHMs). *Journal of Food and Drug Analysis*, *15*(4), 2.
9. Ahmad, I., Ahmad Khan, M. S., &Cameotra, S. S. (2014). Quality assessment of herbal drugs and medicinal plant products. *Encyclopedia of Analytical Chemistry*, *46*, 1-17.

10. Govindaraghavan, S., & Sucher, N. J. (2015). Quality assessment of medicinal herbs and their extracts: Criteria and prerequisites for consistent safety and efficacy of herbal medicines. *Epilepsy &Behavior*, *52*, 363-371.
11. Govindaraghavan, S. (2008). Quality assurance of herbal raw materials in supply chain: challenges and opportunities. *Journal of dietary supplements*, *5*(2), 176-212.
12. Bandaranayake, W. M. (2006). Quality control, screening, toxicity, and regulation of herbal drugs. *Modern phytomedicine: turning medicinal plants into drugs*, 25-57.
13. Calixto, J. B. (2000). Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). *Brazilian Journal of medical and Biological research*, *33*(2), 179-189.
14. Kibwage, I. O., Mwangi, J. W., &Thoithi, G. N. (2005). Quality control of herbal medicines. *East and Central African Journal of Pharmaceutical Sciences*, *8*(2), 27-30.